Skip to main content

Advertisement

ADVERTISEMENT

Poster CS-096

Turning the Tide: A Novel Approach to Calciphylaxis Wound Care Using Hypochlorous Acid

Avigdor NosratiMDLos Robles Regional Medical Centeran468@cornell.edu

Introduction: Calciphylaxis, or calcific uremic arteriolopathy, presents a significant treatment challenge due toits severe pain, chronic wounds, and high mortality. Standard treatments, while varied, frequentlyfail to adequately manage the wound care aspects of this disease.Methods:This case study evaluates the effectiveness of Hypochlorous Acid (HOCl) as the primarytreatment modality for wound care in a 36-year-old female with severe calciphylaxis associatedwith end-stage renal disease, type 2 diabetes mellitus, lupus, and obesity. Her extensive ulcerswere located on her lower abdomen and bilateral lower extremities. Treatment progressionfollowed the transition from conventional agents to HOCl, focusing on outcomes related towound closure, pain management, and overall morbidity.Results:Initial wound care involving traditional methods such as silver sulfadiazine showed minimalimprovement and significant discomfort for the patient. Following the transition to HOCltreatments, significant improvements were noted in wound healing and pain reduction. Over aperiod of four months, the patient achieved complete wound closure and remission ofcalciphylaxis symptoms. The treatment was well-tolerated, with no adverse effects attributed toHOCl.Discussion: The application of HOCl in this case highlights its potential as a superior primary care agent forthe management of calciphylaxis wounds, showcasing a significant departure from moretraditional approaches. HOCl's mechanism, involving the oxidation of microbial cell membranes,offers effective antimicrobial protection without harming human cells. This case underlines theneed for innovative, effective treatments in calciphylaxis management and suggests that HOClcould be considered more broadly in similar clinical scenarios. Future research should focus onrandomized controlled trials to establish definitive evidence of its efficacy and safety in a largercohort of patients with calciphylaxis.References:

Advertisement

Advertisement

Advertisement